ECE2013 Poster Presentations Endocrine tumours and neoplasia (66 abstracts)
Assessment of fatal events in patients with radio-active iodine (RAI)-refractory differentiated thyroid cancer responsive to treatment with sorafenib
Vincenzo Marotta 1 , Michela Del Prete 1 , Valeria Ramundo 1 , Francesca Marciello 1 , Antonella Di Sarno 2 , Raffaella Esposito 1 , Annachiara Carratù 1 , Chiara de Luca di Roseto 1 , Luigi Camera 3 , Annamaria Colao 1 & Antongiulio Faggiano 4
1Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; 2IX Infectious Disease and Interventional Ultrasound Unit, “D. Cotugno” Hospital, Naples, Italy; 3Department of Biomorphological and Functional Sciences, Federico II University, Naples, Italy; 4Endocrinology, National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy.
Introduction: Targeted therapy with the multi-kinase inhibitor sorafenib is effective for treatment of differentiated thyroid cancer (DTC) unresponsive to RAI. Although kinase-inhibitors (KIs) are usually well tolerated, severe and even fatal adverse events are reported. Aim of the study was to assess incidence and characteristics of fatal events in patients with RAI-refractory DTC responsive to treatment with sorafenib.
Design: A retrospective analysis of patients with progressive iodine-refractory DTC subjected to off-label treatment with sorafenib in our centre was performed. Radiological response was assessed according to RECIST criteria version 1.1.
Results: From March 2010, 17 patients affected with RAI-refractory DTC were subjected to treatment with sorafenib. Of them, 12 subjects were responsive to treatment (seven achieved stable disease and five partial response). Median time of treatment for responding patients was 14 months. Fatal events were reported in five of 12 patients (42%). Three patients died from severe haemorrhage of the upper respiratory tract after 4 months of treatment. They had a wide tracheo-oesophageal neoplastic infiltration previously treated with external beam irradiation. Two subjects died from cardiac arrest after 10 months of treatment. They had developed a moderate hypertension after starting treatment with sorafenib.
Conclusions: Although treatment with sorafenib is effective in most patients affected with RAI-refractory DTC, it could be responsible of fatal events. Particularly, bleeding events and cardiac damage are considered as specific adverse events in subjects treated with KIs. In light of this, we suggest to exclude from treatment, or to use a reduced dosage, in those patients with mucosal neoplastic infiltration and those previously treated with radiotherapy. Furthermore, a careful and individualized cardiovascular management is mandatory.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more